Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.83 |
| ▸ | KDR | P35968 | 6/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.83 |
| ▸ | STK10 | O94804 | 1/20 | 0.83 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.83 |
| ▸ | ABL1 | P00519 | 1/20 | 0.83 |
| ▸ | YES1 | P07947 | 1/20 | 0.83 |
| ▸ | RET | P07949 | 1/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.83 |
| ▸ | BCR | P11274 | 1/20 | 0.83 |
| ▸ | FLT1 | P17948 | 1/20 | 0.83 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.83 |
| ▸ | WEE1 | P30291 | 1/20 | 0.83 |
| ▸ | ABL2 | P42684 | 1/20 | 0.83 |
| ▸ | NEK3 | P51956 | 1/20 | 0.83 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.83 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.83 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.83 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.83 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3840840 | 1.00 | EGFR (0.83) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL4767093 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL27585261 | 0.93 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL4769926 | 0.92 | EGFR (0.84) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL27603096 | 0.92 | EGFR (0.84) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93737 | 0.91 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| SCHEMBL93738 | 0.91 | EGFR (0.86) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL1738023 | 0.91 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL29478848 | 0.91 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 | |
| Aee-788 SCHEMBL29973591 | 0.91 | EGFR (1.00) | EGFRKDRERBB2STK10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101103031-B | Pyrrolopyrimidine derivatives for the treatment of proliferative diseases | NOVARTIS AG | 2011-01-19 | — | — | CN | claimed |
| CN-101103031-A | Pyrrolopyrimidine derivatives for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2008-01-09 | — | — | CN | claimed |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | BOLD GUIDO (CH) | 2004-12-09 | — | — | US | claimed |
| US-20040029016-A1 | Polymer electrolyte for lithium-sulfur battery and lithium-sulfur battery comprising same | SAMSUNG SDI CO., LTD. (KR) | 2004-02-12 | — | — | US | claimed |
| CN-101103031-B | Pyrrolopyrimidine derivatives for the treatment of proliferative diseases | NOVARTIS AG | 2011-01-19 | — | — | CN | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-07-03 | — | — | US | disclosed |
| CN-101103031-A | Pyrrolopyrimidine derivatives for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2008-01-09 | — | — | CN | disclosed |
| US-20040029016-A1 | Polymer electrolyte for lithium-sulfur battery and lithium-sulfur battery comprising same | SAMSUNG SDI CO., LTD. (KR) | 2004-02-12 | — | — | US | disclosed |
| US-5663253-A | THICKENERS | 3V INC. (US) | 1997-09-02 | — | — | US | disclosed |
| US-4558108-A | BUTADIENE-STYRENE COPOLYMER AS DISCRETE PARTICLES | XEROX CORPORATION (US) | 1985-12-10 | — | — | US | disclosed |
| EP-0115704-A1 | Aqueous suspension polymerization process | XEROX CORPORATION (US) | 1984-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | EGFR 2358/4885KDR 2667/4885ERBB2 2794/4885 |
| US-20040248911-A1 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, DHPS, TYMP | EGFR 3391/4885KDR 3031/4885ERBB2 2012/4885 |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC1, HDAC2, BAZ2A | EGFR 1171/4885KDR 1887/4885ERBB2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.